{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:35:05Z","timestamp":1772476505465,"version":"3.50.1"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>Overexpression of chemokine receptor subtype 4 (CXCR4) receptors is the root cause of the metastatic spread of various cancers. The use of CXCR4 antagonists as specific ligands to inhibit the CXCR4 interaction with its only natural ligand stromal cell derived factor-1\u03b1 would benefit. Plerixafor is one such Food and Drug Administration approved CXCR4 antagonist used for hematopoietic stem cell mobilization in patients. Taking the specific advantage of low molecular weight, plerixafor conjugation with different bifunctional chelating agents, was optimized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and results<\/jats:title>\n            <jats:p>Radiolabeling of the complex with <jats:sup>68<\/jats:sup>Ga radionuclide was standardized at pH (3\u20138), incubation time (5\u201330\u2009min), temperature (25\u2013100 \u00b0C), and volume (0.5\u20134.5\u2005ml) followed by quality control checks: radionuclide, radiochemical purity, sterility, and pyrogenicity. In-vivo biodistribution studies were performed using gallium-68-diethylenetriamine pentacectic acid (<jats:sup>68<\/jats:sup>Ga-DTPA)-plerixafor in normal rats. The molecular weights of DTPA- and 1,4,7-triazacyclononane-1,4,7-triacetic acid-conjugated plerixafor were 1087 and 1014\u2009Da, respectively. Radiolabeling yield of DTPA conjugated plerixafor was greater than or equal to 99% at pH 5.5; 10\u201315\u2009min incubation at room temperature; and 2.5\u20134.5\u2005ml maximum volume. Radionuclide and radiochemical purities were greater than or equal to 99%. Radiopharmaceuticals were sterile and pyrogen-free. Physiological uptake of <jats:sup>68<\/jats:sup>Ga-DTPA-plerixafor was noted in the spleen (~20% ID\/g), liver (4\u20135% ID\/g), blood pool (6\u201313% ID\/g), and faster clearance via kidneys (18\u201319% ID) up to 180\u2009min.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Radiolabelled <jats:sup>68<\/jats:sup>Ga-DTPA-plerixafor has the potential as a diagnostic carrier molecule for imaging in-vivo CXCR4 expression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mnm.0000000000001998","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T03:00:24Z","timestamp":1750129224000},"page":"726-737","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Bifunctional chelator-plerixafor complex for targeting CXCR4 receptors: radiolabeling, in-vitro, and preclinical study"],"prefix":"10.1097","volume":"46","author":[{"given":"Tamanna","family":"Lakhanpal","sequence":"first","affiliation":[{"name":"Nuclear Medicine and PET Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3355-4168","authenticated-orcid":false,"given":"Jaya","family":"Shukla","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajender","family":"Kumar","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogesh","family":"Rathore","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[{"name":"Clinical Haematology and Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alka","family":"Khadwal","sequence":"additional","affiliation":[{"name":"Clinical Haematology and Medical Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanjit","family":"Bal","sequence":"additional","affiliation":[{"name":"Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagwant Rai","family":"Mittal","sequence":"additional","affiliation":[{"name":"Nuclear Medicine and PET Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"key":"R1-20250709","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1440-1711.1999.00858.x","article-title":"Chemokines and chemokine receptors in infectious diseases.","volume":"77","author":"Mahalingam","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"R2-20250709","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.18632\/oncotarget.1426","article-title":"Chemokines in tumor progression and metastasis.","volume":"4","author":"Sarvaiya","year":"2013","journal-title":"Oncotarget"},{"key":"R3-20250709","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1002\/cmdc.201100320","article-title":"PET imaging of CXCR4 receptors in cancer by a new optimized ligand.","volume":"6","author":"Demmer","year":"2011","journal-title":"ChemMedChem"},{"key":"R4-20250709","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.semcancer.2003.10.003","article-title":"The significance of cancer cell expression of the chemokine receptor CXCR4.","volume":"14","author":"Balkwill","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"R5-20250709","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/bloodadvances.2016003921","article-title":"A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies.","volume":"1","author":"Liu","year":"2017","journal-title":"Blood Adv"},{"key":"R6-20250709","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.bmc.2009.01.014","article-title":"64Cu-AMD3100 \u2013 a novel imaging agent for targeting chemokine receptor CXCR4.","volume":"17","author":"Jacobson","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"R7-20250709","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11307-010-0466-y","article-title":"Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100.","volume":"14","author":"Weiss","year":"2012","journal-title":"Mol Imaging Biol"},{"key":"R8-20250709","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/MNM.0000000000001521","article-title":"Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2\/neu expressing breast cancer patients.","volume":"43","author":"Rathore","year":"2022","journal-title":"Nucl Med Commun"},{"key":"R9-20250709","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-81-322-2607-9_1","article-title":"Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine.","volume":"978","author":"Knapp","year":"2016","journal-title":"Radiopharm Ther"},{"key":"R10-20250709","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/0024-3205(91)90052-D","article-title":"octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sci"},{"key":"R11-20250709","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1021\/ol902601x","article-title":"Total solid-phase synthesis of NOTA-functionalized peptides for PET imaging.","volume":"12","author":"Gu\u00e9rin","year":"2010","journal-title":"Org Lett"},{"key":"R12-20250709","doi-asserted-by":"crossref","first-page":"12462","DOI":"10.1073\/pnas.0705347104","article-title":"[64Cu-NOTA-8-Aoc-BBN (7-14) NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.","volume":"104","author":"Prasanphanich","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"R13-20250709","doi-asserted-by":"crossref","first-page":"108335","DOI":"10.1016\/j.nucmedbio.2023.108335","article-title":"In vivo validation of 68Ga-labeled AMD3100 conjugates for PET imaging of CXCR4.","volume":"120-121","author":"Renard","year":"2023","journal-title":"Nucl Med Biol"},{"key":"R14-20250709","doi-asserted-by":"crossref","first-page":"4707","DOI":"10.3390\/molecules28124707","article-title":"CXCR4-targeted radiopharmaceuticals for the imaging and therapy of malignant tumors.","volume":"28","author":"Yu","year":"2023","journal-title":"Molecules"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T12:01:17Z","timestamp":1752062477000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000001998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":14,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000001998","relation":{},"ISSN":["0143-3636","1473-5628"],"issn-type":[{"value":"0143-3636","type":"print"},{"value":"1473-5628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,17]]}}}